Search Results for: 43

Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023 — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, […]

— Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., March 4,

— Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 — — Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of

— Announced FDA Clearance of IND Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) — — Signed Option License Agreement with Massachusetts General Hospital to Develop SYN-020 to Treat and Prevent Metabolic and Inflammatory Diseases Associated with Aging — — Enrollment in the Phase 2b Investigator-Sponsored Clinical Trial of SYN-010 Has Recommenced Following COVID-19-Related Postponement —

— Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., May 5, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas

— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,

— Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US — ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office

— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company

— Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve